VERY NICE PROFITS ON ELI LILLY – EXCITEMENT OVER ALZHEIMER’S AND WEIGHT LOSS DRUGS

Twitter
LinkedIn
Facebook

By Nigam Arora & Dr. Natasha Arora

Signal Limited is a Signal(s) with a great record in similar situations but does not meet all of the stringent criteria for a Signal.  Typically Signal Limited has higher risk-reward compared to a Signal over the short term. 

Very Nice Profits

The power of buy zones is on display.  Pharmaceutical company Eli Lilly (LLY) stock fell in the buy zone for aggressive investors not that long ago.  The average buy price is $318.45.  It has quickly moved to $435.79 as of this writing.

Drivers

There are two drugs driving Eli Lilly stock higher:

  • Investors are excited, anticipating mega blockbuster drug Mounjaro.  Mounjaro is currently approved for Type 2 Diabetes and could be FDA approved for weight loss as early as the end of the year.
  • Eli Lilly stock took another leg up on strong clinical trial results for its Alzheimer’s drug donanemab.  In a phase III clinical trial, donanemab slowed cognitive decline by 35% and halted early progression of the disease in half of the trial participants.

Bad News

There are safety concerns with donanemab.  Two trial participants had fatal brain swelling.

Approval

Eli Lilly is proceeding with a submission to the FDA for Alzheimer’s drug donanemab.  If approved, donanemab will be the third Alzheimer’s drug on the market.

Pipeline and Portfolio

Eli Lilly has a strong drug pipeline and a competitive portfolio.

Target Zone

LLY stock can easily run much higher.  The new target zone is 🔒 (To see the locked content, please take a 30 day free trial).

Buy Zone

The ideal buy zone is 🔒, but LLY may not fall that low.  For more aggressive investors, the buy zone is 🔒.  The maximum recommended quantity is 🔒.

Stop Zone

The mental stop zone is 🔒.

What To Do Now

Even though the long term target is being raised, in the short term, the stock can easily pull back. Since there are substantial profits, it is simply prudent to book partial profits in the zone of 🔒.

Those not in the stock may consider following the parameters given above.

 

To take a free 30-day trial to paid services to gain access to more opportunities, please click here.

This post was just published on ZYX Buy Change Alert.

Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE 30 day trial.

Nigam Arora

Nigam Arora

Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.

Dr. Natasha Arora

Dr. Natasha Arora

Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.

Subscribe to 'Generate Wealth'

Free Forever

More To Explore

30 Day Free Trial

Cancel within 30 days and you owe nothing

When you take a FREE 30 day trial, you get access to powerful techniques used by billionaires and hedge funds to grow richer. You can continue to use these powerful techniques to grow richer even if you cancel your subscription. You come out ahead by subscribing no matter how you look at it.

Do you want to gain an edge in the markets? Join thousands of your fellow investors and money managers to subscribe to Generate Wealth newsletter.

FREE FOREVER

Follow The Most Accurate Stock Market Analysis

Unrivaled Insights
In Bull and Bear Markets

Generate Wealth Newsletter
Free Forever

Generate Wealth Newsletter
Free Forever